ReviewFrontiers in cardiovascular medicine2022
3D Tissue-Engineered Vascular Drug Screening Platforms: Promise and Considerations.
Review in Frontiers in cardiovascular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 45 citations in OpenAlex.
- Sacrificial Biofabrication for Vascularization: Concept, Materials, Technologies, and Applications.Advanced materials (Deerfield Beach, Fla.) · 2026Review
- Progressing Regenerative Medicine: Integrating Bioprinting Platforms for Stem Cell Applications.Stem cells international · 2026Review
- Advances in 3D-Printed Drug Delivery and Screening Platforms for Bone Disease Therapy.Pharmaceutics · 2025Review
- State of Research on Tissue Engineering with 3D Printing for Breast Reconstruction.Journal of clinical medicine · 2025Review
- Endothelial Cells Increase Mesenchymal Stem Cell Differentiation in Scaffold-Free 3D Vascular Tissue.Tissue engineering. Part A · 2025Article
- Engineering in vitro vascular microsystems.Microsystems & nanoengineering · 2025Review
- Advances and Challenges in 3D Bioprinted Cancer Models: Opportunities for Personalized Medicine and Tissue Engineering.Polymers · 2025Review
- Bridging the gap: From petri dish to patient - Advancements in translational drug discovery.Heliyon · 2025Review
- Ideal animal models according to multifaceted mechanisms and peculiarities in neurological disorders: present and challenges.Archives of pharmacal research · 2025Review
- Organoid models of breast cancer in precision medicine and translational research.Molecular biology reports · 2024Review
- An Arteriovenous Bioreactor Perfusion System for Physiological In Vitro Culture of Complex Vascularized Tissue Constructs.Bioengineering (Basel, Switzerland) · 2024Article
- Targeted Cancer Therapy-on-A-Chip.Advanced healthcare materials · 2024Review
- Plant Cellulose as a Substrate for 3D Neural Stem Cell Culture.Bioengineering (Basel, Switzerland) · 2023Article
- Development of Biocompatible 3D-Printed Artificial Blood Vessels through Multidimensional Approaches.Journal of functional biomaterials · 2023Review
- Alternative Non-Mammalian Animal and Cellular Methods for the Study of Host-Fungal Interactions.Journal of fungi (Basel, Switzerland) · 2023Review
- Control of blood capillary networks and holes in blood-brain barrier models by regulating elastic modulus of scaffolds.Materials today. Bio · 2023Article
- Cancer 3D Models for Metallodrug Preclinical Testing.International journal of molecular sciences · 2023Review
- Steering Stem Cell Fate within 3D Living Composite Tissues Using Stimuli-Responsive Cell-Adhesive Micromaterials.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Next-Generation Microfluidics for Biomedical Research and Healthcare Applications.Biomedical engineering and computational biology · 2023Review
- 3D Models as a Tool to Assess the Anti-Tumor Efficacy of Therapeutic Antibodies: Advantages and Limitations.Antibodies (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the efforts devoted to drug discovery and development, the number of new drug approvals have been decreasing. Specifically, cardiovascular developments have been showing amongst the lowest levels of approvals. In addition, concerns over the adverse effects of drugs to the cardiovascular system have been increasing and resulting in failure at the preclinical level as well as withdrawal of drugs post-marketing. Besides factors such as the increased cost of clinical trials and increases in the requirements and the complexity of the regulatory processes, there is also a gap between the currently existing pre-clinical screening methods and the clinical studies in humans. This gap is mainly caused by the lack of complexity in the currently used 2D cell culture-based screening systems, which do not accurately reflect human physiological conditions. Cell-based drug screening is widely accepted and extensively used and can provide an initial indication of the drugs' therapeutic efficacy and potential cytotoxicity. However,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.